Jim L K
Department of Clinical Pharmacy, King Saud University College of Pharmacy, Riyadh, Saudi Arabia.
Ann Pharmacother. 1993 Jun;27(6):704-7. doi: 10.1177/106002809302700604.
To determine the physical and chemical compatibilities of ciprofloxacin lactate infusion with other commonly used intravenously administered drugs.
Ciprofloxacin lactate injection in a commercially available concentration of 2 mg/mL was mixed with 15 intravenous drugs during simulated Y-site injection. Ciprofloxacin was mixed with usually employed concentrations of other drugs in a 1:1 ratio and examined physically by visual inspection and chemically by HPLC analysis. Adsorption of ciprofloxacin to intravenous administration sets with or without inline filters was also studied.
The study was carried out at ambient temperature (25 degrees C) under fluorescent lighting except for vitamin B complex, which was protected from light. All samples were prepared in a laminar airflow hood.
Physical incompatibility was determined by visual inspection against a black-and-white background, and chemical incompatibility was measured by a stability-indicating HPLC assay for ciprofloxacin. Concentrations determined at time zero (before mixing) were defined as 100 percent. Values estimated for each sample at subsequent time points were calculated as percentages of the initial concentration. Recovery below 90 percent of the initial concentration is defined as significant loss.
Of the 15 drugs studied, only heparin, furosemide, and teicoplanin were found to be incompatible with ciprofloxacin. Adsorption of ciprofloxacin to administration sets with and without inline filters was minimal. Metronidazole was also found to decrease to 90 percent of its initial concentration immediately upon mixing.
Ciprofloxacin ready-to-infuse solution is compatible with most of the drugs studied except heparin, furosemide, teicoplanin, and, perhaps, metronidazole. Because only the stability and potency of ciprofloxacin were studied, further testing is needed to confirm if any chemical deterioration of the other drugs occurred when combined with ciprofloxacin.
确定乳酸环丙沙星注射液与其他常用静脉注射药物的物理和化学相容性。
在模拟Y型接口注射过程中，将市售浓度为2mg/mL的乳酸环丙沙星注射液与15种静脉注射药物混合。环丙沙星与其他药物常用浓度按1:1比例混合，通过目视检查进行物理检查，并通过高效液相色谱分析进行化学检查。还研究了环丙沙星在有无在线过滤器的静脉给药装置上的吸附情况。
除复合维生素B需避光外，研究在室温（25℃）、荧光灯下进行。所有样品均在层流通风橱中制备。
通过在黑白背景下目视检查确定物理不相容性，通过环丙沙星的稳定性指示高效液相色谱法测定化学不相容性。零时间（混合前）测定的浓度定义为100%。在后续时间点为每个样品估计的值计算为初始浓度的百分比。初始浓度回收率低于90%定义为显著损失。
在所研究的15种药物中，仅发现肝素、呋塞米和替考拉宁与环丙沙星不相容。环丙沙星在有和无在线过滤器的给药装置上的吸附最小。还发现甲硝唑在混合后立即降至其初始浓度的90%。
除肝素、呋塞米、替考拉宁以及可能的甲硝唑外，预混型乳酸环丙沙星注射液与大多数所研究药物相容。由于仅研究了环丙沙星的稳定性和效价，因此需要进一步测试以确认其他药物与环丙沙星混合时是否发生任何化学降解。
